期刊文献+

基因病毒治疗系统CNHK300-mIFN-γ治疗肝癌的实验研究

Treatment of hepatocellular carcinoma with gene-viral therapeutic system CNHK300-mIFN-γ
下载PDF
导出
摘要 目的比较基因病毒治疗系统CNHK300-mIFN-γ(以下简称CNHK300-Mγ)与单纯病毒治疗(CNHK300)或基因治疗(AdEasy-mIFN-γ,以下简称AdEasy-Mγ)对裸鼠移植瘤的抑瘤差异。方法观察CNHK300-Mγ、CNHK300和AdEasy-Mγ在裸鼠肝癌SMMC-7721动物模型中的抑瘤差异,并用ELISA法检测血清中mIFN-γ的表达量,HE染色观察肿瘤坏死情况,免疫组织化学染色观察肿瘤内腺病毒外壳蛋白表达情况和肿瘤内微血管生成情况。结果 CNHK300-Mγ具有明显的肿瘤生长抑制作用,与CNHK300、AdEasy-Mγ和对照组的差异均有统计学意义(P<0.05);CNHK300-Mγ组中HE染色肿瘤内见大片坏死,免疫组织化学染色肿瘤内见大量腺病毒外壳蛋白,肿瘤微血管生长明显受抑制,与CNHK300、AdEasy-Mγ和对照组的差异均有统计学意义(P<0.01)。结论基因病毒治疗系统对肿瘤细胞的杀伤能力提高,CNHK300-Mγ能明显抑制肿瘤生长,具有良好的临床应用前景。 Objective To investigate the anti - tumor efficacy of a novel gene - viral therapeutic system CNHK300 - mIFN - γ ( CNHK300 - Mγ) in hepatocellular carcinoma (HCC) xenografts. Methods Cancer cells in log phase were subcutaneously injected into the right flanks of BALB/c nude mice, with administration of 5 × 10^6 SMMC - 7721 per mouse. When SMMC -7721 tumors reached about 50 mm^3, mice were allocated randomly into 4 groups: CNHK300- Mγ, CNHK300, AdEasy- Md and control groups (n = 16). Five intratumoral injections, once every other day, were carried out in subjects, with a total dosage of 109 pfu per mouse in the virus - treated groups and with 100 μL viral preservation solution per mouse per injection in the control group. On the 3rd and 7th day after treatment, groups of 3 mice were sacrificed for collection of serum by retroorbital puncture. ELISA was used for assessment of mlFN - γ. H&E staining and immunohistochemistry were applied for assessment of tumor necrosis and the expression of adenoviral capsid protein hexon, respectively. Results CNHK300 - Mγ/exhibited excellent therapeutic efficacy with tumor inhibition rate, which was significantly higher than that in CNHK300, AdEasy - Mγ/ and control groups (P 〈 0. 05 ). Extensive necrotic foci in pathologic examination were revealed in tumor tissues of CNHK300 - Mγ/ group, compared with those of control group. There were abundant adenoviral capsid protein positive cancer cells in the CNHK300 - Mγ/ group, whereas none was observed in the control group. Meanwhile, significant inhibition of microvessel density was revealed in CNHK300 - Mγ/group, when compared with those in CNHK300, AdEasy - Mγ/ and control groups ( P 〈 0.05 ). Conclusion CNHK300 - Mγ/ can effectively suppress HCC growth through direct viral killing effects and inhibition of tumor angiogenesis, holding a splendid future as a potential antitumor agent.
出处 《广东医学》 CAS CSCD 北大核心 2011年第22期2913-2916,共4页 Guangdong Medical Journal
基金 国家自然科学基金国际合作重大项目(编号:03102160823) 高等学校全国优秀博士论文作者专项资金资助项目(编号:200774)
关键词 腺病毒 端粒酶 基因治疗 肿瘤 Γ干扰素 adenovirus telomerase gene - therapy carcinoma interferon - 3
  • 相关文献

参考文献11

  • 1LIU T C, GALANIS E, KIRN D. Clinical trial results with oneolytie virotherapy: a century of promise, a deeade of progress[ J]. Nat Clin Pract Oncol, 2007, 4(2) : 101 -117. 被引量:1
  • 2QIAN Q, SHAM J, CHE X, et al. C, enevial vectors : a promising way to target tumor cells and express antieancer genes simuhaneously[J]. ChinMedJ(Engl),2002, 115(8): 1213 -1217. 被引量:1
  • 3SU C Q, SHAM J, XUE I-I B, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase -positive cancer cells[J]. J Cancer Res Clin Oncol, 2004, 130 (10) : 591 -603. 被引量:1
  • 4彭林辉,张柏和,张琪,苏长青,崔贞福,钱炎珍,吴孟超,钱其军.携带治疗基因的增殖型腺病毒CNHK300-m干扰素-γ的构建[J].中华实验外科杂志,2007,24(12):1483-1485. 被引量:5
  • 5傅强,王慧萍,韦芳,李慧明,陈霞芳,王煜非,黄倩.一种更有效的肝癌靶向性条件复制型腺病毒的构建及体外抑瘤作用[J].现代生物医学进展,2009,9(10):1801-1804. 被引量:5
  • 6彭林辉,张柏和,吴孟超.端粒酶与肝癌[J].国外医学(肿瘤学分册),2004,31(2):138-141. 被引量:5
  • 7WIRTH T, ZENDER L, SCHULTE B, et al. A telomerase -dependent conditionally replicating adenovirus for selective treatment of cancer[J]. Cancer Res, 2003, 63( 12): 3181 -3188. 被引量:1
  • 8ZHANG Q, NIE M, SHAM J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene [ J ]. Cancer Res, 2004, 64(15), 5390-5397. 被引量:1
  • 9朱颖慧,朱兰才,刘然义,黄文林.干扰素-γ治疗肿瘤的研究进展[J].肿瘤学杂志,2008,14(1):4-9. 被引量:18
  • 10SCHMIDINGER M, STEGER G G, WENZEL C, et al. Sequential administration of interferon gamma and interlcukin-2 in metastatic renal cell carcinoma: results of a phase Ⅱ trial. Austrian Renal Cell Carcinoma Study Group[J]. Cancer Immunol Immunother, 2000, 49 (7) : 395-400. 被引量:1

二级参考文献25

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部